This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Leitzke, S.
Right arrow Articles by Ehlers, S.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Leitzke, S.
Right arrow Articles by Ehlers, S.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, February 1998, p. 459-461, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Rationale for and Efficacy of Prolonged-Interval Treatment Using Liposome-Encapsulated Amikacin in Experimental Mycobacterium avium Infection

S. Leitzke,1,* W. Bucke,2 K. Borner,3 R. Müller,2 H. Hahn,1 and S. Ehlers4

Department of Infectious Diseases, Benjamin Franklin University Clinic, Free University of Berlin, D-12203 Berlin,1 Department of Pharmaceutical Technology, Free University of Berlin, D-12169 Berlin,2 Department of Clinical Chemistry and Clinical Biochemistry, Benjamin Franklin University Clinic, Free University of Berlin, D-12200 Berlin,3 and Division of Molecular Infection Biology, Research Center Borstel, D-23845 Borstel,4 Germany

Received 11 June 1997/Returned for modification 18 August 1997/Accepted 26 September 1997

The potential of liposome-encapsulated antibiotics for prolonging drug application intervals was investigated by using a murine model of chronic lethal Mycobacterium avium infection. Liposomal encapsulation of amikacin, but not of ciprofloxacin, resulted in high and sustained drug levels in infected tissues, exceeding the minimal inhibitory concentration for M. avium for at least 28 days. As a consequence, once-weekly and even once-monthly treatments with liposomal amikacin significantly reduced bacterial replication in infected tissues and extended the survival time of infected mice.


* Corresponding author. Mailing address: Department of Infectious Diseases, Benjamin Franklin University Clinic, Free University of Berlin, Hindenburgdamm 27, D-12203 Berlin, Germany. Phone: 49-30-8445-3654. Fax: 49-30-8445-3830. E-mail: Leitzke{at}zedat.fu-berlin.de.


Antimicrobial Agents and Chemotherapy, February 1998, p. 459-461, Vol. 42, No. 2
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • de Steenwinkel, J. E. M., van Vianen, W., ten Kate, M. T., Verbrugh, H. A., van Agtmael, M. A., Schiffelers, R. M., Bakker-Woudenberg, I. A. J. M. (2007). Targeted drug delivery to enhance efficacy and shorten treatment duration in disseminated Mycobacterium avium infection in mice. J Antimicrob Chemother 60: 1064-1073 [Abstract] [Full Text]  
  • Ellbogen, M. H., Olsen, K. M., Gentry-Nielsen, M. J., Preheim, L. C. (2003). Efficacy of liposome-encapsulated ciprofloxacin compared with ciprofloxacin and ceftriaxone in a rat model of pneumococcal pneumonia. J Antimicrob Chemother 51: 83-91 [Abstract] [Full Text]  
  • Bakker-Woudenberg, I. A. J. M., ten Kate, M. T., Guo, L., Working, P., Mouton, J. W. (2002). Ciprofloxacin in Polyethylene Glycol-Coated Liposomes: Efficacy in Rat Models of Acute or Chronic Pseudomonas aeruginosa Infection. Antimicrob. Agents Chemother. 46: 2575-2581 [Abstract] [Full Text]  
  • Schiffelers, R., Storm, G., Bakker-Woudenberg, I. (2001). Liposome-encapsulated aminoglycosides in pre-clinical and clinical studies. J Antimicrob Chemother 48: 333-344 [Abstract] [Full Text]  
  • Ehlers, S., Richter, E. (2000). Gamma Interferon Is Essential for Clearing Mycobacterium genavense Infection. Infect. Immun. 68: 3720-3723 [Abstract] [Full Text]  
  • Peters, K., Leitzke, S., Diederichs, J. E., Borner, K., Hahn, H., Muller, R. H., Ehlers, S. (2000). Preparation of a clofazimine nanosuspension for intravenous use and evaluation of its therapeutic efficacy in murine Mycobacterium avium infection. J Antimicrob Chemother 45: 77-83 [Abstract] [Full Text]  
  • Quenelle, D. C., Staas, J. K., Winchester, G. A., Barrow, E. L. W., Barrow, W. W. (1999). Efficacy of Microencapsulated Rifampin in Mycobacterium tuberculosis-Infected Mice. Antimicrob. Agents Chemother. 43: 1144-1151 [Abstract] [Full Text]  
  • Barrow, E. L. W., Winchester, G. A., Staas, J. K., Quenelle, D. C., Barrow, W. W. (1998). Use of Microsphere Technology for Targeted Delivery of Rifampin to Mycobacterium tuberculosis-Infected Macrophages. Antimicrob. Agents Chemother. 42: 2682-2689 [Abstract] [Full Text]